MPR7h
Neffy 1mg Approved to Treat Severe Allergic Reactions in Younger Children
The Food and Drug Administration (FDA) has approved neffy ® (epinephrine nasal spray) 1mg for the emergency treatment of type 1 allergic reactions, including anaphylaxis, in pediatric patients aged 4 ...
CMRX Stock Surges on JAZZ Acquisition Bid
Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals JAZZ announced an agreement to acquire Chimerix CMRX. Meanwhile, other pi ...
Zacks Investment Research on MSN3h
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals JAZZ announced an ...
Applied Clinical Trials Online6h
Phase III Trials Confirm Remibrutinib Effectively Reduces Chronic Spontaneous Urticaria Symptoms
Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...
WebMD6h
FDA OKs Nasal Spray for Severe Allergic Reactions in Kids
The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for severe allergic reactions and anaphylaxis.